Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 9/20 | 0.35 |
| ▸ | CDC25B | P30305 | 8/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.34 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.34 |
| ▸ | GJB2 | P29033 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12393373 | 1.00 | PDE2A (0.37) | PDE2AHSPA5PTPN1CDC25BHTR1A | |
| SCHEMBL31063739 | 1.00 | PDE2A (0.37) | PDE2AHSPA5PTPN1CDC25BHTR1A | |
| SCHEMBL27086454 | 1.00 | PDE2A (0.37) | PDE2AHSPA5PTPN1CDC25BHTR1A | |
| SCHEMBL13667906 | 0.92 | HSPA5 (0.38) | PDE2AHSPA5PTPN1CDC25BHTR1A | |
| SCHEMBL18636484 | 0.92 | PDE2A (0.39) | PDE2AHSPA5PTPN1CDC25BHTR1A | |
| SCHEMBL29113115 | 0.92 | PDE2A (0.39) | PDE2AHSPA5PTPN1CDC25BHTR1A | |
| SCHEMBL31725287 | 0.90 | PDE2A (0.38) | PDE2AHSPA5HTR1ATNK2 | |
| SCHEMBL14039002 | 0.89 | PDE2A (0.37) | PDE2AHSPA5PTPN1CDC25BHTR1A | |
| SCHEMBL20756288 | 0.89 | TNK2 (0.33) | TNK2 | |
| SCHEMBL28405132 | 0.89 | BCHE (0.38) | PDE2APTPN1CDC25BHTR1APTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11612614-B2 | Isomorphs of Remdesivir and methods for synthesis of same | Anzalp Pharmasolutions Pvt. Ltd. (IN) | 2023-03-28 | — | — | US | claimed |
| CN-112279855-B | Method for continuously preparing Rudexilvir intermediate by using microchannel reactor | 南京先进生物材料与过程装备研究院有限公司 | 2022-06-14 | — | — | CN | claimed |
| US-20210228605-A1 | ISOMORPHS OF REMDESIVIR AND METHODS FOR SYNTHESIS OF SAME | Anzalp Pharmasolutions Pvt. Ltd. (IN) | 2021-07-29 | — | — | US | claimed |
| US-20210161927-A1 | ISOMORPHS OF REMDESIVIR AND METHODS FOR SYNTHESIS OF SAME | Anzalp Pharmasolutions Pvt. Ltd. (IN) | 2021-06-03 | — | — | US | claimed |
| EP-4705313-A2 | 4'-SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES AS ANTIVIRAL AGENTS | The Scripps Research Institute (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4591935-A2 | METHODS FOR THE PREPARATION OF RIBOSIDES | Gilead Sciences, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-4588928-A2 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-113549120-B | Method for preparing ribonucleoside | 吉利德科学公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-108348526-B | Methods of treating arenaviridae and coronaviridae viral infections | 吉利德科学公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-113493480-B | Preparation and analysis method of Ruidexivir isomer | 南京正大天晴制药有限公司 | 2025-04-15 | — | — | CN | disclosed |
| EP-4036099-B1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250034186-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2025-01-30 | — | — | US | disclosed |
| US-8318682-B2 | 1′substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318682-B2 | 1′substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110230654-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-8008264-B2 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008264-B2 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| WO-2011035250-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612614-B2 | Isomorphs of Remdesivir and methods for synthesis of same | MTAP, SARS1, PNP | PDE2A 782/4885HSPA5 2225/4885PTPN1 2449/4885 |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, MTAP, SLC29A1 | PDE2A 2899/4885HSPA5 2596/4885PTPN1 317/4885 |
| US-20250034186-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, SNRPA | PDE2A 3332/4885HSPA5 1914/4885PTPN1 4217/4885 |
| US-20210228605-A1 | ISOMORPHS OF REMDESIVIR AND METHODS FOR SYNTHESIS OF SAME | MTAP, SARS1, PNP | PDE2A 767/4885HSPA5 2194/4885PTPN1 2471/4885 |
| US-20110230654-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | PNP, TYMP, CDA | PDE2A 2568/4885HSPA5 4599/4885PTPN1 3598/4885 |
| US-20210161927-A1 | ISOMORPHS OF REMDESIVIR AND METHODS FOR SYNTHESIS OF SAME | MTAP, SARS1, PNP | PDE2A 782/4885HSPA5 2225/4885PTPN1 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.